DRMA Dermata Therapeutics Inc revenue, earnings and financials
For the quarter ended June 30, 2026, Dermata Therapeutics Inc reported revenue of n/a, net income of −$2.97M and diluted EPS of −$0.74; for the fiscal year ended December 2025 revenue was n/a.
DRMA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$7.77M, net income −$7.56M (margin n/a), EPS −$8.16
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$12.5M, net income −$12.3M (margin n/a), EPS −$80.32
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$8.04M, net income −$7.79M (margin n/a), EPS −$39.99
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$9.67M, net income −$9.61M (margin n/a), EPS n/a
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$7.86M, net income −$7.90M (margin n/a), EPS n/a
DRMA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$2.97M, EPS −$0.74
- Quarter ended Mar 31, 2026: revenue n/a, net income −$1.85M, EPS −$0.48
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$1.86M, EPS −$0.38
- Quarter ended Sep 30, 2025: revenue n/a, net income −$1.69M, EPS −$1.65
- Quarter ended Jun 30, 2025: revenue n/a, net income −$1.70M, EPS −$1.66
- Quarter ended Mar 31, 2025: revenue n/a, net income −$2.30M, EPS −$4.47
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$3.15M, EPS −$11.03
- Quarter ended Sep 30, 2024: revenue n/a, net income −$3.17M, EPS −$20.41
- Quarter ended Jun 30, 2024: revenue n/a, net income −$2.83M, EPS −$41.82
- Quarter ended Mar 31, 2024: revenue n/a, net income −$3.13M, EPS −$7.06
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$2.13M, EPS n/a
- Quarter ended Sep 30, 2023: revenue n/a, net income −$1.72M, EPS n/a
- Quarter ended Jun 30, 2023: revenue n/a, net income −$1.70M, EPS n/a
- Quarter ended Mar 31, 2023: revenue n/a, net income −$2.24M, EPS n/a
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$1.67M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$2.42M, EPS n/a
- Quarter ended Jun 30, 2022: revenue n/a, net income −$2.73M, EPS n/a
- Quarter ended Mar 31, 2022: revenue n/a, net income −$2.79M, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$2.55M, EPS n/a
- Quarter ended Sep 30, 2021: revenue n/a, net income −$1.71M, EPS −$0.86
DRMA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$7.80M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$11.2M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$6.41M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$8.83M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$5.69M, share buybacks n/a
DRMA balance sheet
- Jun 30, 2026: cash $4.41M, total assets $5.32M, total liabilities $1.83M, shareholders' equity $3.49M
- Mar 31, 2026: cash $6.95M, total assets $7.47M, total liabilities $1.05M, shareholders' equity $6.41M
- Dec 31, 2025: cash $7.52M, total assets $7.86M, total liabilities $1.64M, shareholders' equity $6.22M
- Sep 30, 2025: cash $4.66M, total assets $5.07M, total liabilities $1.11M, shareholders' equity $3.96M
- Jun 30, 2025: cash $6.48M, total assets $6.64M, total liabilities $1.03M, shareholders' equity $5.61M
- Mar 31, 2025: cash $9.72M, total assets $10.0M, total liabilities $2.70M, shareholders' equity $7.30M
- Dec 31, 2024: cash $3.16M, total assets $3.53M, total liabilities $1.97M, shareholders' equity $1.56M
- Sep 30, 2024: cash n/a, total assets $6.69M, total liabilities $1.95M, shareholders' equity $4.74M
Is DRMA profitable?
No. Dermata Therapeutics Inc lost $8.37M over the last four quarters.
What is DRMA's EPS?
Diluted earnings per share over the last four quarters were −$3.25; −$0.74 in the latest quarter.